Multi-Center Data on the use of the BeGraft PLUS in BEVAR cases

E. Verhoeven, A. Katsargyris, P. Marques de Marino, Paracelsus Medical University, Nuremberg, Germany
S. Abisi, St Thomas, London, UK
A. Jawien, NCU Collegium Medicum Bydgoszcz, Poland
T. Jakimowicz, University Warsaw, Poland
Disclosures

• William Cook Europe/Cook Inc.
  – Consultant & Research grants
• Atrium
  – Consultant
• Bentley
  – Part of “Early Launch” Group of the BeGraft+
  – Consultant
Lay-Out

• Why Be-Graft+?

• Multicenter Data
  – London, Warszow, Bydgoszcz, Nuremberg
Launch BeGraft peripheral

Launch BeGraft peripheral - modified design -

Launch BeGraft peripheral PLUS
## Radial Force

<table>
<thead>
<tr>
<th></th>
<th>Lifestream (8x58mm)</th>
<th>ADVANTA V12 (8x59mm)</th>
<th>BGP (8x57mm)</th>
<th>BGP+ (8x57mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radial Force (N/mm)</td>
<td>2.09</td>
<td>3.05</td>
<td>3.52</td>
<td>6.94</td>
</tr>
</tbody>
</table>

*(n = 4)*
Kink-Resistant

Lifestream (8x58mm)
Advanta V12 (8x59mm)
BeGraft (8x57mm)
BeGraft PLUS (8x57mm)
Case Example #1

- 79 YO Male
- Type III TAAA
  - Dmax: 67mm
- Comorbidity
  - CAD
  - 2x Previous Laparotomy

- Plan: 4x BEVAR (2 stages)
BeGraft +
Celiac Trunk
BeGraft$^+$
Celiac Trunk
Postop CTA
Case Example #6

- 68 YO Male
- Suprarenal AAA
  - Dmax: 58 mm
- Previous Aortobifem
- Comorbidity
  - CAD
    - EF: 35%
- Plan: 4x BEVAR (2 stages)
Renal Arteries
BeGraft+ RRA
Final Angiography
BeGraft+
Multicenter Experience
(01/2017-12/2018)

- London, UK (S. Abisi) N=92
- Warsaw, Poland (T. Jakimowicz) N=85
- Bydgoszcz, Poland (A. Jawien) N=56
- Nuremberg, Germany N=74

Total Vessels targeted with BeGraft+: N=307
Patients
Procedures

• TAAA: N= 106
• Pararenal AAA: N= 9
• IBD: N= 16

TOTAL: N=131
Target Vessels

- RA: $N=142$
- CT: $N=73$
- SMA: $N=61$
- IIA: $N=31^*$

**TOTAL:** $N=307$

*Includes also IBDs within TAAA procedures*
Technical Success
(Target vessel related)

• 98.7% (303/307)*
  – 4 Intraop-Early Postop Occlusions, all RAs
    • 3 Recanalised Successfully

*2 Additional BeGraft+ Stent-grafts not used (introduction problems)
Primary Relining
(with SE uncovered Stent)

• N= 69 (22.5%)
Primary Patency

98.4 ± 0.8% at 6 months
95.0 ± 3.5% at 12 months
Freedom from Reintervention

98.6 ± 0.8% at 6 months
98.6 ± 0.8% at 12 months
Conclusions

• BeGraft\textsuperscript{+} new Generation Covered Stent
  – „BEVAR“ dedicated
  – Visibility +++, Flexibility +++, Kink Resistant +++
  – Transition with Target Vessel?
    • Still a reason to reline sometimes?
• Multicenter Data
  – ↑Initial Technical success rates
    • Excellent patency & ↓Need for Reintervention
Multi-Center Data on the use of the BeGraft PLUS in BEVAR cases

E. Verhoeven, A. Katsargyris, P. Marques de Marino, Paracelsus Medical University, Nuremberg, Germany

S. Abisi, St Thomas, London, UK

A. Jawien, NCU Collegium Medicum Bydgoszcz, Poland

T. Jakimowicz, University Warsaw, Poland